We are live on ! Find out more
XFOR icon

X4 Pharmaceuticals
XFOR

Fund managers haven’t disclosed any holdings of XFOR yet.

XFOR Hedge Fund Activity: Q1 2026 in Review

84 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in X4 Pharmaceuticals (XFOR) for Q1 2026, worth a combined $388M — up 8.5% from $358M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new XFOR positions and 11 closed out — a net gain of 7 holders — while 22 added to existing stakes and 23 trimmed.

The largest buyer was Deep Track Capital, adding an estimated $4.97M. The largest seller was Siren LLC, exiting entirely with an estimated $6M sold.

  • 84 institutional investors held X4 Pharmaceuticals (XFOR) as of Q1 2026, up from 79 in Q4 2025.
  • Funds reported $388M of X4 Pharmaceuticals stock for Q1 2026, up 8.5% quarter-over-quarter.
  • 18 funds opened new X4 Pharmaceuticals positions in Q1 2026 and 11 closed out, a net change of +7 holders.
  • The largest X4 Pharmaceuticals buyer in Q1 2026 was Deep Track Capital, an estimated $4.97M added.
  • The largest X4 Pharmaceuticals seller in Q1 2026 was Siren LLC, an estimated $6M sold.

Based on aggregated 13F filings for Q1 2026.